182 related articles for article (PubMed ID: 4043181)
1. In vivo and in vitro antiestrogenic action of 3-hydroxytamoxifen, tamoxifen and 4-hydroxytamoxifen.
Löser R; Seibel K; Roos W; Eppenberger U
Eur J Cancer Clin Oncol; 1985 Aug; 21(8):985-90. PubMed ID: 4043181
[TBL] [Abstract][Full Text] [Related]
2. Biological activities of tamoxifen aziridine, an antiestrogen-based affinity label for the estrogen receptor, in vivo and in vitro.
Wei LL; Mangel WF; Katzenellenbogen BS
J Steroid Biochem; 1985 Dec; 23(6A):875-81. PubMed ID: 3937947
[TBL] [Abstract][Full Text] [Related]
3. Differential antiestrogen action in the immature rat uterus: a comparison of hydroxylated antiestrogens with high affinity for the estrogen receptor.
Jordan VC; Gosden B
J Steroid Biochem; 1983 Sep; 19(3):1249-58. PubMed ID: 6684713
[TBL] [Abstract][Full Text] [Related]
4. Physicochemical and genetic evidence for specific antiestrogen binding sites.
Faye JC; Jozan S; Redeuilh G; Baulieu EE; Bayard F
Proc Natl Acad Sci U S A; 1983 Jun; 80(11):3158-62. PubMed ID: 6574477
[TBL] [Abstract][Full Text] [Related]
5. Antiestrogenic properties of keoxifene, trans-4-hydroxytamoxifen, and ICI 164384, a new steroidal antiestrogen, in ZR-75-1 human breast cancer cells.
Poulin R; Merand Y; Poirier D; Levesque C; Dufour JM; Labrie F
Breast Cancer Res Treat; 1989 Oct; 14(1):65-76. PubMed ID: 2605344
[TBL] [Abstract][Full Text] [Related]
6. Induction of two estrogen-responsive proteins by antiestrogens in R27, a tamoxifen-resistant clone of MCF7 cells.
Vignon F; Lippman ME; Nawata H; Derocq D; Rochefort H
Cancer Res; 1984 May; 44(5):2084-8. PubMed ID: 6713400
[TBL] [Abstract][Full Text] [Related]
7. Antitumor actions of keoxifene and tamoxifen in the N-nitrosomethylurea-induced rat mammary carcinoma model.
Gottardis MM; Jordan VC
Cancer Res; 1987 Aug; 47(15):4020-4. PubMed ID: 3607747
[TBL] [Abstract][Full Text] [Related]
8. Binding characteristics of novel nonsteroidal antiestrogens to the rat uterine estrogen receptors.
Martel C; Provencher L; Li X; St Pierre A; Leblanc G; Gauthier S; Mérand Y; Labrie F
J Steroid Biochem Mol Biol; 1998 Feb; 64(3-4):199-205. PubMed ID: 9605415
[TBL] [Abstract][Full Text] [Related]
9. Importance of the alkylaminoethoxy side-chain for the estrogenic and antiestrogenic actions of tamoxifen and trioxifene in the immature rat uterus.
Jordan VC; Gosden B
Mol Cell Endocrinol; 1982 Aug; 27(3):291-306. PubMed ID: 7128917
[No Abstract] [Full Text] [Related]
10. Comparison of the physicochemical properties of uterine nuclear estrogen receptors bound to estradiol or 4-hydroxytamoxifen.
Attardi B; Happe HK
Endocrinology; 1986 Aug; 119(2):904-15. PubMed ID: 3732150
[TBL] [Abstract][Full Text] [Related]
11. Interaction of DP-TAT-59, an active metabolite of new triphenylethylene-derivative (TAT-59), with estrogen receptors.
Toko T; Matsuo K; Shibata J; Wierzba K; Nukatsuka M; Takeda S; Yamada Y; Asao T; Hirose T; Sato B
J Steroid Biochem Mol Biol; 1992 Nov; 43(6):507-14. PubMed ID: 1419885
[TBL] [Abstract][Full Text] [Related]
12. Time-related effects of a triphenylethylene antiestrogen on estrogen-induced changes in uterine weight, estrogen receptors, and endometrial sensitivity in rats.
Trivedi RN; Chauhan SC; Dwivedi A; Kamboj VP; Singh MM
Contraception; 1995 Jun; 51(6):367-79. PubMed ID: 7554978
[TBL] [Abstract][Full Text] [Related]
13. Possible mechanisms for the agonist actions of tamoxifen and the antagonist actions of MER-25 (ethamoxytriphetol) in the mouse uterus.
Lyman SD; Jordan VC
Biochem Pharmacol; 1985 Aug; 34(15):2795-806. PubMed ID: 4015716
[TBL] [Abstract][Full Text] [Related]
14. Comparative pharmacodynamic analysis of TAT-59 and tamoxifen in rats bearing DMBA-induced mammary carcinoma.
Toko T; Shibata J; Sugimoto Y; Yamaya H; Yoshida M; Ogawa K; Matsushima E
Cancer Chemother Pharmacol; 1995; 37(1-2):7-13. PubMed ID: 7497599
[TBL] [Abstract][Full Text] [Related]
15. Differential induction of progestin-binding sites in uterine cell types by estrogen and antiestrogen.
Ennis BW; Stumpf WE
Endocrinology; 1988 Oct; 123(4):1747-53. PubMed ID: 3416812
[TBL] [Abstract][Full Text] [Related]
16. Structure-activity relationships of nonisomerizable derivatives of tamoxifen: importance of hydroxyl group and side chain positioning for biological activity.
Murphy CS; Parker CJ; McCague R; Jordan VC
Mol Pharmacol; 1991 Mar; 39(3):421-8. PubMed ID: 2005879
[TBL] [Abstract][Full Text] [Related]
17. Antiestrogenic and antitumor effects of droloxifene in experimental breast carcinoma.
Kawamura I; Mizota T; Mukumoto S; Manda T; Masuda K; Nakamura T; Kubota H; Matsumoto S; Nishigaki F; Shimomura K
Arzneimittelforschung; 1989 Aug; 39(8):889-93. PubMed ID: 2818677
[TBL] [Abstract][Full Text] [Related]
18. Opposing biological actions of antiestrogens in vitro and in vivo: induction of progesterone receptor in the rat and mouse uterus.
Campen CA; Jordan VC; Gorski J
Endocrinology; 1985 Jun; 116(6):2327-36. PubMed ID: 3996316
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of the uterotropic activity of estrogens and antiestrogens by the short acting antiestrogen LY117018.
Jordan VC; Gosden B
Endocrinology; 1983 Aug; 113(2):463-8. PubMed ID: 6872937
[TBL] [Abstract][Full Text] [Related]
20. TAT-59, a new triphenylethylene derivative with antitumor activity against hormone-dependent tumors.
Toko T; Sugimoto Y; Matsuo K; Yamasaki R; Takeda S; Wierzba K; Asao T; Yamada Y
Eur J Cancer; 1990 Mar; 26(3):397-404. PubMed ID: 2141500
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
